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Risk for cognitive impairment among 
HIV-infected persons with bipolar disorder
Clinicians and clinical neuroscientists are aware that individuals with bipolar disorder are at
greater risk for developing serious medical, psychiatric, and substance-use comorbidities as
compared with the general population.
1,2 Less widely appreciated, however, is the observation
that HIV infection appears to be more prevalent among persons with bipolar disorder and that
both conditions pose significant risk for cognitive impairment.
3 Higher rates of HIV infection
among persons with bipolar disorder should not be surprising, given that infection and trans-
mission of HIV involves risk factors that converge with bipolar disorder (eg, impulsivity, sub-
stance abuse).These factors likely also worsen adherence to treatment for both bipolar and HIV
illness, and may adversely impact health-related quality of life and therapeutic outcomes.The
public health consequence may be that nonadherence to antiretroviral therapy could lead to
higher rates of transmission of treatment-resistant strains of HIV that can evolve with sporadic
adherence.The intersection of bipolar disorder and HIV therefore merits discussion by clini-
cians, researchers, and policy makers.
If mental health clinicians adopt the recent Centers for
Disease Control recommendation that all persons in clin-
ical care be tested for HIV,we might expect that more
HIV-infected persons with bipolar disorder will be iden-
tified who had not previously been diagnosed or treated
for existing HIV infection.
4When addressing the com-
plex combination of HIV infection,substance abuse or
dependence,and bipolar disorder,it is important to rec-
ognize that each of these factors may be associated with
substantial cognitive deficits. These neurocognitive
impairments may impact on the ability to function in
social and occupational settings,to follow through with
treatment recommendations, and to manage their
demanding medical conditions.
Below we review the evidence for neuropsychological
(NP) impairment among persons with bipolar disorder,
HIV infection,and substance dependence (ie,metham-
phetamine dependence) as independent disorders.Our
hypothesis,and the basis for our ongoing research,is that
the presence of significant medical comorbidities (eg,
HIV infection) and substance use (eg,methamphetamine
dependence) may further compound the risk for additive
neurocognitive impairments among persons with bipolar
disorder.We describe our new program of research in
bipolar disorder and comorbid HIV, and present data
showing elevated rates of methamphetamine depen-
dence among persons with bipolar disorder.Finally,we
discuss how cognitive impairment may be a significant
predictor of everyday functioning difficulties (eg,med-
ication nonadherence).
Neuropsychological impairment among 
persons with bipolar disorder
Recent studies of individuals with bipolar disorder sug-
gest that NP impairment is prevalent,and intermediate
in severity between patients with schizophrenia and
healthy comparison participants.
5-8 NP impairments,par-
ticularly deficits in attention,processing speed,episodic
memory,and executive functions (eg,set-shifting,com-
plex problem-solving), are thought to persist during
euthymic states between episodes (Table I).
9-14
Neuropsychological impairment among 
persons with HIV infection
HIV infection is characterized by an acute,often febrile,
phase lasting days or weeks, a prolonged medically
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asymptomatic period,and a symptomatic phase of mul-
tisystem disease caused by immunosupression. HIV is
also known to cause neuropsychological (NP) impair-
ments, particularly in the areas of attention/working
memory,motor coordination,processing speed,learning,
and attention (Table I).
15,16 NP impairment tends to
worsen with disease severity,with the greatest NP impair-
ments observed among individuals with AIDS.
16 HIV
enters the central nervous system soon after infection,
and mild cognitive impairment has been observed in
approximately 30% of medically asymptomatic HIV-
infected patients,whereas some form of NP impairment
is observed in over 50% of individuals in later-stage HIV
disease.
15Although antiretroviral treatments have greatly
improved the longevity and quality of life for persons liv-
ing with HIV infection,the prevalence of HIV-associated
neurocognitive disorders (HAND) has not declined.
17
Neuropsychological impairment among
methamphetamine users
Persons with bipolar disorder and individuals with HIV are
at increased risk for both alcohol and other substance abuse
and dependence.
2,18The NP impairments associated with
various drugs of abuse differ; however, most illicit sub-
stances and alcohol,when used in significant quantities or
over a substantial period of time,are likely to produce mea-
surable neurocognitive deficits that may persist for
extended periods,even after abstinence is achieved.Here,
we focus on the neuropsychological difficulties associated
with methamphetamine use disorders because:(i) its use is
on the rise in the United States
19;(ii) cognitive impairments
are common and substantial among abusers;and (iii) it is
the most frequently abused substance,aside from marijuana
and alcohol,worldwide.
20A recent review and meta-analy-
sis showed that methamphetamine abuse or dependence
resulted in neuropsychological impairments of medium
effect size in the domains of episodic memory,executive
functioning,information processing speed,motor skills,lan-
guage, and visuoconstructive abilities.
21 The cognitive
domains with the largest effect sizes are listed in Table I.
Furthermore,evidence suggests that when methampheta-
mine abuse or dependence is combined with HIV infection,
there is additive neuropsychological impairment.
22,23
Preliminary descriptive data on HIV-positive
persons with bipolar disorder as compared
with HIV-positive persons without bipolar
disorder
We recently began prospective research studies in order
to understand better the neuropsychological and everyday
functioning (eg,medication adherence) difficulties among
persons with bipolar disorder and HIV infection.Although
these studies are ongoing and final results are not avail-
able,we show some of the descriptive data (Table II) for a
group of HIV-positive (HIV+) bipolar disorder (BD) par-
ticipants (HIV+/BD+) as compared with HIV+ persons
without bipolar disorder (HIV+/BD-).
Prospective bipolar participants were recruited for par-
ticipation if they reported a previous diagnosis of bipo-
lar disorder and were currently taking medications to
treat their bipolar disorder and HIV infection.A diag-
nosis of Bipolar I or II was assigned by administering the
gold standard psychodiagnostic assessment (Structured
Clinical Interview for DSM-IV);alcohol and substance
abuse and dependence diagnoses were determined via
the Composite International Diagnostic Interview.
Individuals with methamphetamine-induced mania were
excluded.No other restrictions were placed on recruit-
ment.Demographically similar (eg,age,education,eth-
nicity,sex,socioeconomic status) HIV+ comparison par-
ticipants were recruited if they were taking a medication
to treat their HIV illness.Comprehensive neuromedical,
neuropsychological,and medication adherence evalua-
tions were conducted.
Demographic, psychiatric, and substance dependence
information from these two groups are presented (Table
II).By design,participants were similar in terms of demo-
graphic characteristics including age,education,ethnicity,
and sex. Twelve of the participants had a diagnosis of
Bipolar I,and an additional 3 participants had a diagnosis
of Bipolar II.Half (9/18) of the participants in the HIV+
Bipolar disorder HIV Methamphetamine
Learning/memory Learning Learning/memory
Processing speed Processing speed Processing speed
Attention/ Attention/ Executive functions
working memory working memory
Executive Functions Motor skills
Table I. Overlap in neurocognitive domains commonly impaired among
bipolar disorder, HIV infection, and methamphetamine
abuse/dependence. 
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group without bipolar disorder met criteria for a lifetime
diagnosis of Major Depressive Disorder (MDD);however,
only 11% (2/18) met criteria for a current depressive
episode.Twenty-seven percent (4/15) of participants in the
bipolar group met criteria for a current depressive episode
and an equivalent amount (27%;4/15) met criteria for a
current manic episode (2 manic episodes, 1 hypomanic
episode,1 extreme irritability episode).Also as anticipated,
participants in the bipolar group tended to take a greater
number of psychotropic medications;93% (14/15) in bipo-
lar group were taking more than one psychotropic med-
ication as compared with 33% (6/18) in the group without
bipolar disorder.The bipolar group also had higher scores
on both the Young Mania Rating Scale and the Beck
Depression Inventory-II, and lower scores on global
assessment of functioning.
The rates of current alcohol, marijuana, and metham-
phetamine dependence were relatively low in both groups;
however,rates of lifetime marijuana and methampheta-
mine dependence were elevated among participants with
bipolar disorder and HIV infection as compared with
those with HIV alone,and rates of lifetime alcohol depen-
dence were elevated in both groups (Table II). When
examining abuse or dependence of methamphetamine
instead of focusing exclusively on dependence,65% (9/15)
of the bipolar group met criteria for lifetime metham-
phetamine abuse or dependence as compared with 28%
(5/18) in the group without bipolar disorder.
Detailed neuropsychological test results are pending larger
sample sizes; however, with the cognitive impairments
found in both bipolar disorder and persons with metham-
phetamine dependence, we anticipate significant neu-
ropsychological impairments among our participants with
both bipolar disorder and HIV infection, and possibly
even greater impairments among those with bipolar dis-
order,HIV infection,and methamphetamine dependence.
Implications of impaired cognition for every-
day functioning among persons with bipolar
disorder
Cognitive impairment appears to be one of the strongest
predictors of everyday functioning difficulties in several
populations including bipolar disorder
24 and HIV infec-
tion.
25 Medication adherence,an extremely important daily
activity for persons with significant medical or psychiatric
problems,appears to be consistently related to cognitive
abilities among individuals with HIV infection
26-28 and per-
sons with bipolar disorder.
29-31
Specific deficits in the NP domains of executive function-
ing,attention,and memory have been shown to be associ-
ated with poor medication adherence.
26Therefore,the con-
vergence of risk for cognitive impairment among persons
with comorbid HIV,BD,and methamphetamine abuse or
dependence may make persons with these multiple risk
factors particularly susceptible to nonadherence and other
everyday functioning difficulties (Figure 1).
HIV+/BD+ HIV+/BD- 
(n=15) (n=18)
Demographic
Age  44.2 (9.8) 48.4 (9.0)
Education  13.9 (2.3) 12.9 (2.1)
Male 87% (13/15) 78% (14/18)
Caucasian 87% (13/15) 72% (13/18)
Currently employed  40% (6/15) 32% (6/18)
Psychiatric
Lifetime BD I* 80% (12/15) N/A
Lifetime diagnosis of MDD  N/A 50% (9/18)
Current MDE 27% (4/15) 11% (2/18)
Current hypomanic/manic episode 27% (4/15) N/A
Psychiatric medications, no 3.1 (1.4) 1.3 (1.6)
YMRS 7.5 (7.0) 2.7 (2.6)
BDI-II Total 13.7 (12.1) 11.7 (7.9)
GAF Score 64.6 (13.5) 75.1 (11.6)
Substance dependence
Alcohol abuse (current) 33% (5/15) 22% (4/18)
Alcohol dependence (current) 13% (2/15) 22% (4/18)
Alcohol abuse (lifetime) 53% (8/15) 56% (10/18)
Alcohol dependence (lifetime) 60% (9/15) 50% (9/18)
Marijuana abuse (current) 27% (4/15) 11% (2/18)
Marijuana dependence (current) 7% (1/15) 6% (1/18)
Marijuana abuse (lifetime) 40% (6/15) 33% (6/18)
Marijuana dependence (lifetime) 33% (5/15) 11% (2/18)
Methamphetamine abuse (current) 7% (1/15) 11% (2/18)
Methamphetamine dependence (current) 0% (0/15) 6% (1/18)
Methamphetamine abuse (lifetime) 47% (7/15) 22% (4/18)
Methamphetamine dependence (lifetime) 40% (6/15) 22% (4/18)
Table II. Demographic, psychiatric, and substance abuse/dependence
characteristics of study group (HIV+/BD+ v. HIV+/BD-). Data are
mean (SD) or percent (n). * Other bipolar participants are bipo-
lar II (n=3). BD, bipolar disorder; BDI-II, Beck Depression
Inventory – II; GAF, Global Assessment of Function Scale; MDD,
Major Depressive Disorder; MDE, Major Depressive Episode;
YMRS, Young Mania Rating Scale259
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Summary
Persons with bipolar disorder are at risk for medical and
psychiatric comorbidities,including those known to inde-
pendently cause neuropsychological impairment (eg,
HIV infection,methamphetamine dependence).We sug-
gest that these conditions may confer additional risk for
the development of neuropsychological impairment
among persons with bipolar disorder.We speculate that
cognitive difficulties in bipolar HIV+ patients may
impact medication adherence and other everyday func-
tioning tasks.Poor adherence to psychotropics may lead
to mood destabilization,whereas inconsistent adherence
to antiretroviral medications may lead to the develop-
ment of treatment-resistant strains of HIV. Substance
abuse may further destabilize the care of these individu-
als and may additionally contribute to cognitive impair-
ments.
Additional research is needed to better understand the
neuropsychological abilities of patients with bipolar dis-
order and other serious comorbidities, including the
extent of impairment, its features, likelihood for pro-
gression,relationship to HIV exposure,and impact on
everyday functioning abilities among the multiply
affected.The exact relationship between bipolar disorder
and methamphetamine abuse and dependence also war-
rants further investigation.Finally,targeted interventions
for complex cases at risk for neuropsychological impair-
ment are needed (see Depp et al in this issue, p 239);
improving medication adherence seems to be one area
for intervention that is important and attainable. ❏
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Figure 1. Bipolar disorder, HIV, and substance abuse may lead to neuropsychological impairments that may impact everyday functioning activities such as med-
ication adherence. Medication nonadherence may then in turn exacerbate both HIV and bipolar disorder. 260
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